Glofitamab in relapsed/refractory diffuse large B cell lymphoma: Real world data

Basit Öğe Kaydı
dc.authorid0000-0003-1237-8281
dc.authorid0000-0001-9636-4113
dc.contributor.authorFerhanoğlu, Burhan
dc.contributor.authorGülbaş, Zafer
dc.contributor.authorUzay, Ant
dc.contributor.authorÖzcan, Muhit
dc.contributor.authorÖzkalemkaş, Fahir
dc.contributor.authorDal, Mehmet Sinan
dc.contributor.authorKalyon, Hakan
dc.contributor.authorAkay, Olga Meltem
dc.contributor.authorDeveci, Burak
dc.contributor.authorBekoz, Hüseyin
dc.contributor.authorSevindik, Ömür Gökmen
dc.contributor.authorToptaş, Tayfur
dc.contributor.authorYılmaz, Asu Fergün
dc.contributor.authorKoyun, Derya
dc.contributor.authorAlkış, Nihan
dc.contributor.authorBirtaş Ateşoğlu, Elif
dc.date.accessioned2023-03-10T08:13:18Z
dc.date.available2023-03-10T08:13:18Z
dc.date.issued2022
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractAbstract INTRODUCT ?ION Glofitamab is a T-cell-engaging bispecific antibody connecting CD20 on B cells and CD3 on T cells. Although, most of the patients with B-cell non-Hodgkin lymphoma (BNHL) achieve complete response (CR) following firstline treatment with rituximab and chemotherapy, about 40% of patients with diffuse large B-cell lymphoma (DLBCL) is refractory or relapse (R/R). Autologous stem-cell transplantation (ASCT) can cure some of these patients but many patients cannot undergo this procedure. CAR-T therapies are a significant advance but not available in many countries like Turkey. In Phase II expansion study, the overall response rate (ORR) was 51.6% and complete remission (CR) rate was 39.4% in R/R DLBCL patients (Dickinson er al. JCO 2022). In this retrospective study, we aimed to report the outcomes of patients who used glofitamab via compessionate use in Turkey.
dc.identifier.citationFerhanoğlu, B., Gülbaş, Z., Uzay, A., Özcan, M., Özkalemkaş, F., Dal, M. S. ... Birtaş Ateşoğlu, E. (2022). Glofitamab in relapsed/refractory diffuse large B cell lymphoma: Real world data. Blood içinde (6704-6705. ss.). https://doi.org/10.1182/blood-2022-165385
dc.identifier.doi10.1182/blood-2022-165385
dc.identifier.endpage6705
dc.identifier.issn0006-4971
dc.identifier.issn1528-0020
dc.identifier.issueSupplement: 1
dc.identifier.startpage6704
dc.identifier.urihttps://doi.org/10.1182/blood-2022-165385
dc.identifier.urihttps://hdl.handle.net/20.500.12511/10604
dc.identifier.volume140
dc.identifier.wos000893223206319en_US
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.institutionauthorBekoz, Hüseyin
dc.institutionauthorSevindik, Ömür Gökmen
dc.language.isoen
dc.publisherAmerican Society of Hematology
dc.relation.ispartofBlooden_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectRelapsed/Refractory
dc.subjectReal World Data
dc.subjectDiffuse Large B Cell
dc.titleGlofitamab in relapsed/refractory diffuse large B cell lymphoma: Real world data
dc.typeConference Object

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Bekoz-Hüseyin-2022.pdf
Boyut:
394.73 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Bildiri Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu